This week, Johnson & Johnson JNJ began the third-quarter earnings season for the drug and biotech sector. The FDA granted ...

Layoffs resulted at the plant "to ensure capacity is effectively utilized based on projected product demands," the company ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

We recently compiled a list of the 8 Good Stocks To Buy Right Now. In this article, we are going to take a look at where ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to be looking for bargains all the more intently. On average, the ...

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older ...

Merck's P/S multiple is roughly 4, and its P/FCF is 21. That makes its valuation a bit pricier than Pfizer's per dollar of revenue, but significantly cheaper per dollar of free cash flow. In other ...

Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

The health sector sees dynamic changes as Gerresheimer's shares rise due to activist investor interest, while Australia and ...

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...